Fig. 3From: A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resectionForest plot of RFS outcomes in patients who received sorafenib therapy for HCC after resection. RFS, recurrence-free survival; HCC, hepatocellular carcinomaBack to article page